GFAP-based gene therapy for treatment of retinal diseases

File
Date Issued
2005-11
Note

PATENT STATUS: Pending. Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.

Language
Type
Genre
Extent
31p.
Identifier
15800
Additional Information
PATENT STATUS: Pending. Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid constructs and vectors.
Date Backup
2005-11
Date Text
2005-11
Date Issued (EDTF)
2005-11
Extension


FAU
FAU
admin_unit="FAU01", ingest_id="dep129388_ing1512", creator="creator:CTHOMAS", creation_date="2007-07-19 13:32:46", modified_by="super:FAUDIG", modification_date="2014-02-25 11:35:22"

IID
FADT15800
Organizations
Person Preferred Name

Dorey, C. Kathleen

creator

Physical Description

PDF
31p.
Title Plain
GFAP-based gene therapy for treatment of retinal diseases
Origin Information

2005-11
Title
GFAP-based gene therapy for treatment of retinal diseases
Other Title Info

GFAP-based gene therapy for treatment of retinal diseases